FDA Expands Agilent's Cancer Test Approval to Four New Tumor Types
A sits 25% above its 52-week low of $108.35.
Summary
The FDA has granted expanded approval for Agilent's PD-L1 cancer test, now covering esophageal squamous cell carcinoma, triple-negative breast cancer, cervical cancer, and gastric/gastroesophageal junction. This approval also consolidates all existing and new indications onto the Dako Omnis platform, streamlining testing for labs. This significantly broadens the market and utility of Agilent's companion diagnostic, developed with Merck for Keytruda, and enhances the Dako Omnis platform's value.
At the time of this announcement, A was trading at $134.93 on NYSE in the Life Sciences sector, with a market capitalization of approximately $38.2B. The 52-week trading range was $108.35 to $160.27. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.